RSS-Feed abonnieren
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.1055/s-0043-102916
Redefinition of Parkinson’s Disease
Publikationsverlauf
Publikationsdatum:
02. Mai 2017 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00033101/201702/lookinside/thumbnails/12_10-1055-s-0043-102916-1.jpg)
Abstract
In 2015, a working group of the International Parkinsonʼs and Movement Disorders Society (MDS) presented new clinical diagnostic criteria for Parkinsonʼs disease (PD). This review outlines the key insights with regard to pathophysiology, various clinical manifestations and clinical progression which form the basis for a redefinition and the new, summarized clinical diagnostic criteria of Parkinson’s disease. Essential findings, which led to the new diagnostic criteria, include (i) the recognition of the importance of non-motor symptoms, which may have a tremendous influence on the quality of life of patients and have an increasing relevance with regard to early and differential diagnosis of PD is stated. (ii) The categorization of dementia in the course of Parkinson’s disease. While there has been a clear separation between Parkinson’s disease and dementia with Lewy bodies so far, now a continuum is postulated which summarizes Parkinson’s disease without, with late and with early (within the first year after the occurrence of motor symptoms) dementia under the umbrella term of Lewy Body Diseases (LBD). (iii) The realization of a slowly spreading process of neurodegeneration occurring throughout different parts of the nervous system. This resulted in the definition of different phases of the disease, the preclinical, prodromal and clinical phase. In particular, the definition of the prodromal phase, characterized by different clinical parameters and further biomarkers still to be implemented, opens up new possibilities for early diagnosis and in the long run early treatment of Parkinson’s disease. (iv) The insight that the clinical phase is characterized by different forms of disease progression. For genetic variants (e. g., GBA or LRRK2) a separate clinical-genetic category is proposed, in idiopathic Parkinson’s disease subtypes should be characterized by clearly distinct prognosis, progression and/or treatment strategies. The MDS Task Force proposes to keep the current gold standard of typical clinical motor symptom presentation and post-mortem verification of α-synucleinopathy for the diagnosis of PD. The new clinical diagnostic criteria were designed using a typical clinical expert as benchmark, codifying the expert diagnostic process to make it reproducible and easily applicable. The new diagnostic criteria now contain absolute exclusion criteria, supportive criteria and “red flags” in addition to the assessment of the cardinal motor symptoms. Specific ancillary diagnostic tests (e. g., imaging techniques) can be implemented; furthermore the time course and severity of symptoms are taken into account.
-
References
- 1 Berg D, Postuma RB, Bloem B. et al. Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson’s disease. Mov Disord 2014; 29: 454-462
- 2 Postuma RB, Berg D, Stern M. et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 2015; 30: 1591-1601
- 3 Berg D, Postuma RB, Adler CH. et al. MDS research criteria for prodromal Parkinson’s disease. Mov Disord 2015; 30: 1600-1611
- 4 Antonini A, Barone P, Marconi R. et al. The progression of non-motor symptoms in Parkinson’s disease and their contribution to motor disability and quality of life. J Neurol 2012; 259: 2621-2631
- 5 Santos-Garcia D, de la Fuente-Fernandez R. Impact of non-motor symptoms on health-related and perceived quality of life in Parkinson’s disease. J Neurol Sci 2013; 332: 136-140
- 6 Prakash KM, Nadkarni NV, Lye WK. et al. The impact of non-motor symptoms on the quality of life of Parkinson’s disease patients: A longitudinal study. Eur J Neurol 2016; 23: 854-860
- 7 McKeith I. Dementia with Lewy bodies. Dialogues Clin Neurosci 2004; 6: 333-341
- 8 Goldman JG, Williams-Gray C, Barker RA. et al. The spectrum of cognitive impairment in Lewy body diseases. Mov Disord 2014; 29: 608-621
- 9 Lees AJ. When did Ray Kennedy’s Parkinson’s disease begin?. Mov Disord 1992; 7: 110-116
- 10 Braak H, Del Tredici K, Rub U. et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003; 24: 197-211
- 11 Adler CH, Beach TG. Neuropathological basis of nonmotor manifestations of Parkinson’s disease. Mov Disord 2016; 31: 1114-1119
- 12 Luk KC, Song C, O’Brien P. et al. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci USA 2009; 106: 20051-20056
- 13 Kordower JH, Chu Y, Hauser RA. et al. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson’s disease. Nat Med 2008; 14: 504-506
- 14 Shannon KM, Keshavarzian A, Mutlu E. et al. Alpha-synuclein in colonic submucosa in early untreated Parkinson’s disease. Mov Disord 2012; 27: 709-715
- 15 Lebouvier T, Chaumette T, Damier P. et al. Pathological lesions in colonic biopsies during Parkinson’s disease. Gut 2008; 57: 1741-1743
- 16 Stokholm MG, Danielsen EH, Hamilton-Dutoit SJ. et al. Pathological alpha-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients. Ann Neurol 2016; 79: 940-949
- 17 Mollenhauer B, Locascio JJ, Schulz-Schaeffer W. et al. alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 2011; 10: 230-240
- 18 Majbour NK, Vaikath NN, van Dijk KD. et al. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease. Mol Neurodegener 2016; 11: 7
- 19 Nandhagopal R, Mak E, Schulzer M. et al. Progression of dopaminergic dysfunction in a LRRK2 kindred: A multitracer PET study. Neurology 2008; 71: 1790-1795
- 20 Stoessl AJ. Positron emission tomography in premotor Parkinson’s disease. Parkinsonism Relat Disord 2007; 13 (Suppl. 03) S421-S424
- 21 Berg D, Seppi K, Behnke S. et al. Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: A 37-month 3-center study of 1847 older persons. Arch Neurol 2011; 68: 932-937
- 22 Iranzo A, Fernandez-Arcos A, Tolosa E. et al. Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients. PLoS One 2014; 9: e89741
- 23 Schenck CH, Boeve BF, Mahowald MW. Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: A 16-year update on a previously reported series. Sleep Med 2013; 14: 744-748
- 24 Gonera EG, van’t Hof M, Berger HJ. et al. Symptoms and duration of the prodromal phase in Parkinson’s disease. Mov Disord 1997; 12: 871-876
- 25 Masliah E, Rockenstein E, Adame A. et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson’s disease. Neuron 2005; 46: 857-868
- 26 Mandler M, Valera E, Rockenstein E. et al. Next-generation active immunization approach for synucleinopathies: Implications for Parkinson’s disease clinical trials. Acta Neuropathol 2014; 127: 861-879
- 27 Benner EJ, Mosley RL, Destache CJ. et al. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson’s disease. Proc Natl Acad Sci USA 2004; 101: 9435-9440
- 28 Rajput AH, Voll A, Rajput ML. et al. Course in Parkinson disease subtypes: A 39-year clinicopathologic study. Neurology 2009; 73: 206-212
- 29 Fereshtehnejad SM, Romenets SR, Anang JB. et al. New Clinical Subtypes of Parkinson Disease and Their Longitudinal Progression: A Prospective Cohort Comparison With Other Phenotypes. JAMA Neurol 2015; 72: 863-873
- 30 Brockmann K, Srulijes K, Hauser AK. et al. GBA-associated PD presents with nonmotor characteristics. Neurology 2011; 77: 276-280
- 31 Healy DG, Falchi M, O’Sullivan SS. et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: A case-control study. Lancet Neurol 2008; 7: 583-590
- 32 Marras C, Lang A, van de Warrenburg BP. et al. Nomenclature of genetic movement disorders: Recommendations of the international Parkinson and movement disorder society task force. Mov Disord 2016; 31: 436-457
- 33 Poulopoulos M, Levy OA, Alcalay RN. The neuropathology of genetic Parkinson’s disease. Mov Disord 2012; 27: 831-842
- 34 Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 1988; 51: 745-752
- 35 DelleDonne A, Klos KJ, Fujishiro H. et al. Incidental Lewy body disease and preclinical Parkinson disease. Arch Neurol 2008; 65: 1074-1080
- 36 Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease. Neurology 2001; 57: 1497-1499
- 37 Kim JS, Park IS, Park HE. et al. alpha-Synuclein in the colon and premotor markers of Parkinson disease in neurologically normal subjects. Neurol Sci 2017; 38: 171-179
- 38 Cersosimo MG, Perandones C, Micheli FE. et al. Alpha-synuclein immunoreactivity in minor salivary gland biopsies of Parkinson’s disease patients. Mov Disord 2011; 26: 188-190
- 39 Del Tredici K, Hawkes CH, Ghebremedhin E. et al. Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson’s disease. Acta Neuropathol 2010; 119: 703-713
- 40 Donadio V, Incensi A, Leta V. et al. Skin nerve alpha-synuclein deposits: A biomarker for idiopathic Parkinson disease. Neurology 2014; 82: 1362-1369
- 41 Rodriguez-Leyva I, Calderon-Garciduenas AL, Jimenez-Capdeville ME. et al. alpha-Synuclein inclusions in the skin of Parkinson’s disease and parkinsonism. Ann Clin Transl Neurol 2014; 1: 471-478
- 42 Skogseth RE, Bronnick K, Pereira JB. et al. Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson’s Disease. J Parkinsons Dis 2015; 5: 783-792
- 43 Stav AL, Aarsland D, Johansen KK. et al. Amyloid-beta and alpha-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson’s disease. Parkinsonism Relat Disord 2015; 21: 758-764